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hydrated silica gel layer, which served as a nucleation site
for CaP crystal deposition, and then subsequent dissolution.
Thereafter, most glass compositions used for bioactive pur
FIELD OF THE INVENTION
poses contained from 30 to 60 Wt. % Sio2, since it was
This invention relates to materials having the capacity to 5 widely accepted that the formation of hydroxyapatite would
occur on particles with a silica-rich layer.
form a calcium phosphate (CaP) layer thereon. These mate
Neo et al., “Difference in Ceramic-Bone Interface
rials are ceramic, glass, glass-ceramic or partially crystalline
Between Surface-Active Ceramics and Resorbable Ceram
and are bioactive in that they are osteoconductive, osteoics; A Study by Scanning and Transmission Electron
stimulatory or osteogenic nature when contacted with physi
ologic solutions, including mammalian bodily fluids and 10 Microscopy,” J. Biomed. Mater. Res., 26, 255-267 (1992),
recognize that surface active glasses and glass ceramics
tissues. This invention also provides rapid methods of pro
bond to bone through an intervening hydroxyapatite layer.
ducing CaP (Hydroxyapatite (HAp) and amorphous HAp)
When in contact with bodily fluids, the surface of the silicate
on the surface of a bioactive material.
glass is transformed into a silica-rich layer onto which
15 calcium and phosphorus ions from the surrounding fluids
BACKGROUND OF THE INVENTION
precipitate as a calcium phosphate hydroxyapatite layer.
Certain prior ceramic compositions, especially glass and
This intervening hydroxyapatite layer is free of collagen and
glass-ceramic, are known to support the bonding, growth or
composed of fine granular apatite crystals distinct from
genesis of bone by fostering a supportive environment
those of bone.
between the material and living, bone progenitor cells. It is
20
The process of synthesizing hydroxyapatite is often time
widely recognized that successful bioactive glasses include
consuming. Processes such as precipitation, hydrolysis, or
silica in order to foster the needed supportive environment.
the use of sol gel usually require several steps over several
These compositions are considered bioactive since they
weeks to form hydroxyapatite, and yet, stochiometric
possess surfaces capable of fostering a calcium phosphate
hydroxyapatite cannot be achieved easily. Even 45S5, which
layer which, in turn, promotes bone bonding to the material.
25 provides a surface for the formation of HAp, have in vivo
Bioactive materials of the type described herein include
reactions that occur slowly prior to fully bonding to bone.
surface-active materials such as those disclosed in U.S. Pat.
There are few alternative ceramic compositions that are
No. 5,204,106, Schepers, et al., termed 45S5 glass which are
capable of supporting bone growth without silica playing a
of the composition Na20.C a0P20 5.Si02.
When implanted, bone formation has been observed in 30 critical role in the formation process.
Bioactive glasses have been very successful in the pro
45S5 as occurring throughout the entire defect through
motion of bone growth via a HAp layer, but there are
osteogenesis via osteostimulation, assisted by osteoconducproblems. By enlarging the range of starting materials, the
tion due to the calcium phosphate layer that is formed prior
drawbacks found in present materials such as those relying
to the central, cellular mediated disintegration. As used
herein, osteoconduction generally means the apposition of 35 chiefly on the presence of silica, may be avoided. Alternative
starting materials such as those containing borate may also
growing bone to the three dimensional surface of a suitable
produce HAp at a faster rate.
scaffold provided by a graft. Osteogenesis, as used herein,
Accordingly, it is the object of this invention to provide
generally means the process of bone formation through
alternative bioactive materials that are bioactive when used
cellular osteoblastic activity. Osteostimulation, as used
herein, generally means the promotion of bone growth. 40 in vivo.
Upon central disintegration, the bioactive glass particles are
It is also the object of this invention to provide more rapid
fully transformed into calcium phosphate. The composition
methods for producing CaP on a bioactive glass.
and size of the preferred granules in Schepers et al., are such
Additional objects, advantages and novel features of this
that the particles are gradually transformed as the defect site
invention will become apparent to those skilled in the art
becomes vascularized and populated with bone tissue 45 upon examination of the following descriptions, figures and
forming cells.
claims thereof, which are not intended to be limiting.
Kokubo et al., “Chemical Reaction of Bioactive Glass and
BRIEF DESCRIPTION OF THE DRAWINGS
Glass-Ceramics with a Simulated Body Fluid,” J Mater.
FIG.
1 shows a graph of reaction layer growth on 45B5-1
Sci.: Mater. Med 3, 79-83 (1992), among others, have
described the need for a hydroxyapatite layer to promote 50 glass spheres in 1 M phosphate at different temperatures.
These measurements are each the average of six spheres.
bone bonding since hydroxyapatite, whose stochiometric
Full reaction of the spheres occurred in 24, 18, and 4 hours
composition is Ca10(PO4)6(OH)2, is the major inorganic
at 37° C., 47° C., and 57° C., respectively.
component of living bone. It is biocompatible with hard and
FIG. 2 shows the X-Ray diffraction (XRD) patterns of A)
soft tissues when used as implants. The crystallinity of HAp
varies with the maturity of the bone, can contain carbonate, 55 well crystallized HAp, B) synthetic HAp, C) the inorganic
component of bone and D) 45B5-1 reacted with 1 M
and can be calcium or phosphate deficient.
phosphate solution for 24 hours at 37° C.
The drive to form hydroxyapatite on glass materials led
FIG. 3 is a table depicting a summary of reactions of
Hench and others to use 45S5 glass as a starting material (L.
45S5c (partially crystallized 45S5) and 45B5-1 glass spheres
L. Hench, R. J. Splinter, T. K. Greenlee, and W. C. Allen,
“Bonding Mechanisms at the Interface of Ceramic Pros 60 in ly d P C ^ solutions.
FIG. 4 shows the XRD patterns of 45B5-1 glass spheres
thetic Materials,” J Biomed Mater. Res. Symp. 117-141
75 to 150 pm in diameter reacted with 1 M (A) and 0.1 M
(1971)). The theory of apatite formation was extensively
(B) solution at 37° C., initial pH=7. The main HAp peaks are
explained through the necessary steps of the formation of a
marked with arrows and indicated by the lines at the bottom
hydrated silica gel layer inducing and promoting the nucleation of apatite. When alkali silicate glasses dissolved, alkali 65 of each figure.
ions at the glass surface were selectively exchanged for
FIG. 5 shows the XRD patterns of 45B5-1 glass spheres
hydronium ions in the surrounding solution, leaving a
reacted in 0.01 M (A) and 0.001 M (B) solution at 37° C.,
BIOACTIVE MATERIALS
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initial pH=7. Only a weak HAp XRD pattern appears after
ranging from about 0.001 M to about 1 M. Preferably, the
112 days of reaction (16 weeks).
concentration is about 0.1 M or about 0.01 M. More
preferably, the concentration is about 1 M. The phosphate
FIG. 6 depicts the appearance of hydroxyapatite crystals
solutions have an initial pH in the range of about 6 to about
on the surface of 45B5-1 glass spheres reacted for 1, 4, 11,
and 26 days in a 1 M K2HP0 4 solution at 37° C. of starting 5 10 .
pH of 7 (respectively A, B, C and D).
While providing faster methods for producing CaP on
bioactive glasses, the invention can be conducted in a
FIG. 7 depicts the appearance of the surface of 45B5-1
temperature range of about 30° C. to about 60° C.
glass spheres (A) and the surface underneath the plate layer
Preferably, the temperature range is about 35° C. to about
(B and C) reacted for 16 weeks (112 days) in a 0.001 M
10 57° C. In another embodiment, the reaction takes place at a
K2H P04 solution at 37° C. of starting pH of 7.
constant temperature of about 37° C. The process features a
FIG. 8 shows 45B5-1 glass microspheres immersed in 1
flexible reaction time from about 4 hours to about 2 weeks.
M Na2H P04 solution at 37° C. at initial, 6 hour, 18 hour and
The reaction time period can be about 5 days to about 14
24 hour times. The bubbles shown in the initial frame are a
days. A preferable time for the reaction is between about 4
result of flame spheroidization.
15 hours to about 24 hours. In some embodiments the reaction
FIG. 9 depicts XRD patterns of 45B5-1 reacted with 1 M
time can be about 24 hours.
phosphate for 1, 4, and 1 1 days, and the documented XRD
Certain embodiments of this invention provide bioactive
pattern for Hap.
ceramic materials comprising borate glass that possess a
FIG. 10 shows 45B5-1 glass microspheres, after immer
calcium phosphate layer. As used herein, borate glass refers
sion in 1 M Na2H P04 solution for 24 hours at 37° C., which 20 to a m aterial having a general com position of
were subsequently mounted in polymethyl methacrylate
Na20.C a0P20 5.B20 3 in some embodiments. 45B5-1 borate
(PMMA) and cross-sectioned. The cavities or dark spots
glass embodies certain aspects of this invention having the
inside the microspheres are gas bubbles formed during
aforementioned composition. Typical embodiments of this
spheroidization.
invention are a ceramic material wherein Na20 is from
25
FIG. 11 depicts surface apertures of 45B5-1 (A and B)
about 20% to about 35%; CaO is from about 20% to about
glass spheres reacted in 1 M lydP C ^ solutions for 5 days).
35%; P20 5 is from about 0% to about 10%; and B203 is from
about 30% to about 50%. In more typical embodiments
FIG. 12 depicts a cross section of a rat tibia containing
Na20 is from about 22% to about 30%, CaO is from about
45B5-1 glass particles implanted for 15 days in vivo. The
22% to about 30%, P20 5 is from about 5% to about 6%,
black lines denote the edges of the initial hole. New bone
(shown by black arrows) has formed on the edge of the holes 30 B203 is from about 35% to about 50%. The ranges disclosed
herein include all combinations and subcombinations of
and around the particles, but the holes are still open.
ranges and specific percentages therein. In some preferred
FIG. 13 depicts a cross section of a rat tibia containing
embodiments, there is about 22.9% Na20 , about 22.9%
45B5-1 glass particles after 30 days in vivo. The particles of
45B5-1 are surrounded by new bone and the original holes 35 CaO, about 5.6% P20 5 and about 48.6% B203. The per
centages disclosed herein are meant to include the percent
are sealed.
composition by weight. In other embodiments, it is foresee
SUMMARY OF THE INVENTION
able that the borate glass material can contain Li20 or K20.
As used herein, ceramic is considered all materials that
Notwithstanding its inexhaustible embodiments, the
invention is bioactive materials having the formula 40 are inorganic, nonmetallic solids. They can be metal oxides
but many ceramics are also compounds of metallic elements
xNa20.yCa0.zP20 5.qB20 3 wherein x is from about 20% to
and carbon, nitrogen, or sulfur. In atomic structure they are
about 35% by weight; y is from about 20% to about 35% by
most often crystalline, although they also may contain a
weight; z is from about 0% to about 10 % by weight; and q
combination of glassy and crystalline phases. As used
is from about 30% to about 50% by weight. The bioactive
materials can be ceramic, glass, glass-ceramic or a crystal 45 herein, glass is considered a non-crystalline inorganic solid
material that can be transparent or translucent as well as hard
line material. Many embodiments have a calcium phosphate
and brittle. As used herein, glass-ceramic is considered a
surface layer upon the bioactive material and in others, the
glass with crystalline components.
calcium phosphate layer is hydroxyapatite. The invention
also forms a calcium phosphate layer when in contact with
Typical embodiments of the invention are at least partially
a physiological solution. In preferred embodiments, x is 50 crystalline. 50% to 80% of the material may be crystalline.
22.9%, y is 22.9%, z is 5.6% and q is 48.6%. The invention
In other embodiments 30% to 50% may be crystalline and in
can also take the form of particles that have a particle size
more typical embodiments, less than 30% to less than 1%
range from about 1 fim to about 400 fim. Preferably, the
can by crystalline.
range can be from about 40 fim to about 300 fim, or 60 fim
The invention provides a bioactive ceramic that is pre
to about 250 fim. More preferably the range can be from 55 reacted to give a calcium phosphate layer disposed upon the
about 75 fim up to about 1 mm. The invention can be
ceramic. This layer is a hydroxyapatite layer in some
generally spherical, morselized, in coating form or in bulk.
embodiments that may be preferred. The formation of the
The invention can also be fibrous or foliaceous.
HAp layer on the borate glass of the present invention may
The invention is a particulate borate ceramic, the particles
be formed by reacting the glass with phosphate ions and is
of the ceramic being at least a partial calcium phosphate 60 related to the pH change of the solutions that harbor the
layer thereupon.
glass. The pH of solutions that interact with the borate
ceramic display a general increase within the first two
This invention is also a process for providing a bioactive
weeks. This is likely due to the high (25 mol %) alkali
material comprising reacting a material having the formula
content of the material, which in turn increases solution
xNa20.yCa0.zP20 5.qB20 3 with an aqueous solution com
prising phosphate ions for a time sufficient to dispose CaP 65 alkalinity. It is generally observed that the final pH increases
by 1.5 to 3 units in solutions of 0.1 M phosphate and lower.
upon said material. The aqueous solutions used in the
This high solution alkalinity promotes ion leaching from the
process can be Na2H P04 or K2H P04 with concentrations
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material. Initially, sodium ions in the ceramic are replaced
subcombinations of ranges and specific temperatures
with hydrogen ions from solution to form hydroxyl groups.
therein. Formation of HAp on the material of the invention
These hydroxyl groups react with the structural bonds
occurs within a range of 24 to 4 hours and all combinations
between boron and oxygen, setting the boron ions free. As
and subcombinations of ranges and specific times therein
the ion exchange proceeds into the bulk of the ceramic, there 5 when reacted in a 1 M aqueous phosphate solution at
is an increase in the surface area of the ceramic and
temperatures ranging from 37° C. to 57° C. (FIG. 1). At
dissolution occurs/proceeds from the surface inward. The
other concentrations, reaction time can vary from 4 hours to
pH of the solution eventually stabilizes since the ion con
2 weeks. At 0.1 M and 1 M, HAp can form at 37° C., the
centration gradient (potential for exchange of ions between
preferred temperature for the production of an implantable
the solution and the glass) reaches steady state. Precipitation 10 bioactive glass material, in 14 and 5 days, respectively. The
of a layer of calcium phosphate occurs from the ionic
time needed to produce an adequate layer of HAp varies
reaction between calcium and phosphate within the ceramic
with changes in the temperature of the reaction and/or the
and in the solution. Over a number of days, the thickness of
concentration of the phosphate solution. It is appreciated
this precipitated surface layer increases.
that there are circumstances when these variables can be
General embodiments of the invention include a particu 15 altered for the specific purposes of the producer.
According to certain embodiments of this invention, the
late borate ceramic, the particles being at least a partial
HAp on the ceramic enables the bioactive material to mimic
calcium phosphate layer thereupon. The particles are gen
the natural bone processes of osteoconduction, osteogenesis,
erally found in a crushed state, 300 fim to 355 fim approxi
and osteostimulation. The bioactive material of the many
mate size range. Embodiments can have a general diameter
ranging from about 1 fim to about 1 mm, or 40 fim to about 20 embodiments of this invention is rendered osteoconductive,
osteostimulatory, or osteogenic when contacted with mam
400 fim. Preferably, the diameter range is about 60 fim to
malian bodily fluids.
about 250 fim with 75 fim to about 150 fim being the most
preferred. As used herein, the diameter range is measured by
Certain embodiments of this invention demonstrate a
standard techniques including scanning electron microscopy
lower melting temperature and a broader range of solubility
25
(SEM) photos that had a calibrated length scale and using
when compared with 45S5 (melting temperatures 1300°
sieves of known openings.
C.-14000 C.). Absent also are any of the physiologic con
cerns that may be associated with having silica. Certain
The ceramic material can also come in the form of
embodiments of this invention are impenetrable to X-rays
microspheres, morsels, fibers, flakes or even in bulk. It is
and are therefore radiopaque, which has important medical
appreciated that since the diameter range may vary, the
30
implications, since it is often necessary or desirable to
shape of glass particles will also vary in their microspherical
visualize the material once implanted (in vivo).
form. Therefore, their shape may be generally spherical. If
the glass is not spheroidized but left in a crushed state, it is
Under in vivo conditions, the reaction of the bioactive
considered to be in morsel form. As used herein, the foliaparticles occurs through the uniform continuous leaching of
ceous shapes are considered those shapes having leaflike or
Na+, B+3 and Ca30 2 from the ceramic. It has been deter
flake-like structures. As used herein, the fibrous shapes are 35 mined that there is no shrinkage of the particles during the
considered those structures having, consisting of or resem
reaction of the material in Na2H P04 solution or in simulated
bling fibers. As used herein, bulk forms are considered those
body fluids. Further, HAp formation on the surface of
that encompass a variety of shapes or forms in a large
45B5-1 has similar crystal shape, size and degree of crys
volume or mass. The material may also be used as a coating
tallinity as natural bone when reacted with phosphate solu
for other materials suitable for implantation within the body. 40 tions. FIG. 2 shows the XRD pattern of the inorganic
component of bone, synthetic HAp, well-crystallized HAp
A subset of embodiments of this invention includes meth
and 45B5-1 microspheres reacted with 1 M phosphate
ods for making a bioactive glass material are provided. A
solution for one day at 37° C. The XRD pattern of 45B5-1
material having the formula Na2O.CaO.P2O5.B2O3 is
reacted with an aqueous solution comprising phosphate ions 45 reacted with 1 M phosphate solution for 24 hours at 37° C.
(FIG. 2D) is quite similar to the patterns for natural bone
for a time sufficient to form calcium phosphate upon said
(FIG. 2C) and synthetic HAp (FIG. 2B), which indicates that
material. Solutions comprising phosphate ions used in many
the degree of crystallinity of the reacted 45B5-1 is close to
preferred embodiments of this invention include Na2H P04
natural bone. The shape and size of HAp crystals are also
and K2H P04. In other embodiments, acids containing phos
phate ions, such as H3P 0 4, are reacted with the material. 50 similar in the reacted 45B5-1 microspheres and living bone.
In one embodiment, a HAp layer can be formed on the
HAp formation is observed on XRD patterns of 45B5-1
surface of 45B5-1 glass particles when reacted in aqueous
after 1, 4, and 11 days in Na2H P04 solution. IR spectra
phosphate ion solutions within a general range of 0.001 M
confirm the presence of HAp structures on the reacted
to 1 M and all combinations and subcombinations of ranges
ceramic. ICP analysis demonstrates the decrease in the
and specific concentrations therein concentrations at 37° C. 55 amount of phosphorus and the total absence of calcium in
and starting pH of 7. The rate of formation is more apparent
the reacting solution after 80 days. The ICP results indicate
at 0.1 M and 1 M wherein formation occurs from 14 days to
that the phosphorus combines with the calcium from the
as few as 5 days, respectively. The rate of formation is
glass to form HAp. SEM combined with EDS has estab
slower for phosphate solutions of lower concentrations
lished the presence of calcium and phosphate on the surface
within a general range of 0.001 M to 0.01 M and all 60 of the 45B5-1 spheres reacted in phosphate ion solutions
combinations and subcombinations of ranges and specific
ranging from 0.001 M to 1 M.
concentrations therein. However, the slower rates of the
The invention is further unique in that it fosters the growth
latter concentrations may be more favorable depending on
of CaP and is bioactive while being substantially free of
the aims of the procedure for which the ceramics are being
silica. As used herein, substantially silica-free means less
used.
65 than 10% silica in some embodiments, fewer than 5% in
The reaction can occur at constant temperatures generally
others, and less than 2% in many. In more typical
within the 30° C. to 60° C. range and all combinations and
embodiments, the amount of silica is limited to that amount
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which will not interfere with the basic functions of this
those in the 75-150 fim size range, which were used for
invention. In some embodiments that may be preferred, the
experimentation. Other irregular particles in the size range
invention contains only a trace of silica amounting to less
of 45-75 fim were also used.
than 0.25% by weight.
The spheres were produced in a vertical, electrically
According to the ICP data, a uniform dissolution process 5 powered tube furnace. A hot zone, 127 cm in length, was
sufficient to spheroidize the borate glass particles at 1000° C.
of borate spheres that are silica-free occurs in aqueous
The particles were dropped into the top of the furnace tube
phosphate solutions. In these phosphate solutions, a uniform
and the spheres collected at the bottom of the furnace tube
dissolution releases all the sodium and phosphorous ions
in a glass jar. The tube was tightly sealed to prevent chimney
contained in the borate glass system without forming a
borate gel. The absence of such a gel greatly lowers the 10 effect, convection currents, in the tube. The annealing tem
perature of the glass was determined using differential
interaction of the particles with the surrounding liquids,
thermal analysis (DTA). The spheres were annealed at 450°
leading to a lower viscosity of the solid liquid suspension
C. for an hour and cooled to room temperature.
and a free flowing of the particles with body fluids. The
calcium phosphate combines and freely precipitates on the
The density of the glass particles and spheres was mea
surface of the glass spheres without the need for a silica gel 15 sured by a standard picnometer procedure using ethanol. The
nucleating agent, which was once believed necessary to
density measured for the 45B5-1 spheres and particles was
foster bone growth on glass material.
around 2.16±0.2. The density indicated that the spheroidization process did not change the final density between glass
The substantially silica-free borate glass materials
particles and spheres.
embodied in this invention react faster when compared to
the reaction kinetics of 45S5 glasses. The formation of a 20
DTA and Thermo-Gravimetric Analysis (TGA) were per
crystalline HAp layer on the 45S5 silicate glasses depends
formed on 45B5-1 glass using a Netzsch STA 409 at a
on several variables including the rate of ion exchange,
heating rate of 15° C. per minute in air. These techniques
hydroxylation of the glass surface and pH and ion concen
were used to determine the glass transition temperature and
tration of the solution. XRD data shows a crystalline HAp
weight loss on heating from 22° C. to the melting tempera
pattern in 28 days for partially crystallized 45S5 glass 25 ture.
spheres reacted in 0.1 M solution of starting pH of 7,
The onset of crystallization for the 45B5-1 glass occurred
whereas, it takes only 14 days for HAp to appear in the XRD
at 572° C.±5° C. and subsequent melting was found at 864°
pattern for silica-free borate glass reacted in the same
C.±2° C. (The glass transition temperature for the 45B5-1
solution. FIG. 3 shows the reaction products of 45S5c and
glass was determined to be around 505° C.±5° C.) Little
30
45B5-1 in phosphate solutions of varying molarity.
measurable weight loss of 0.03 wt % was observed over a
Unlike 45S5 glasses, the rate of formation of HAp on the
temperature range of 1 00° C. to 1150° C.
surface of the bioactive borate ceramic of the present inven
To produce a layer of HAp on the surface of the particles,
tion can occur within as few as 5 days. This is a result of the
the 45B5-1 glass particles were reacted for 24 hours in a 1
generally lower chemical durability of borate ceramic when 35 M Na2H P04 solution with a starting pH of 7 at 37° C. The
compared to silicate glass, which in turn affects the rate of
phosphate solution was prepared by dissolving the appro
dissolution of the borate ceramic. Borate ceramics of the
priate amount of reagent grade Na2H P04 (Fisher Scientific,
present invention tend to dissolve more uniformly/
St. Louis, Mo.) in distilled water acidified with 1.5 M HC1.
consistently since the dissolution rate of borate ceramic is
After complete dissolution of the Na2H P04, the pH was
controlled by bulk dissolution instead of the dissolution of a 40 adjusted to 7 with 1.5 M tris (hydroxymethyl) amisingle species within the ceramic. Further, since no silica is
nomethane.
present in the borate ceramic, no potentially problematic
Example—2
(biocompatibility-wise) silica layer is formed during the
dissolution process. Additionally, borate ceramics can be
Phosphate Solutions
formed at lower temperatures-lower melt/processing tem 45 K2H P04 Solutions
peratures. In vivo, bone growth around bioactive borate
Partially crystallized 45S5 glass spheres, hereinafter
ceramic particles is faster than the growth associated with
referred to as 45S5c, and 45B5-1 glass spheres were reacted
silicate glass particles implanted under similar conditions.
in K2H P04 solutions at a constant temperature of 37° C. The
45S5c glass was reacted in solutions of 1, 0.1, 0.01, and
EXAMPLES
50 0.001 M K2H P04 at a starting pH of 7, 8 and, 9.5. The
45B5-1 glass was reacted in solutions of 1, 0.1, 0.01, and
Example—1
0.001 M K2H P04 at starting pH of 7.
The phosphate solutions were prepared in glass beakers
Glass Particle Preparation and Pre-Reaction Process
by dissolving the appropriate amounts of l^HPC^ reagent
45B5-1 borate glass of composition of 48.6% B20 3 22.9% 55 grade in distilled water. The pH was monitored and adjusted
CaO, 22.9% Na20 , and 5.6% P20 5 Wt % was prepared
with HC1 to obtain the desired starting pH value. The HC1
using H3BO3, CaC03, Na2C 0 3, and Na2H P04 (Fisher
used was diluted with distilled water to a concentration of
Scientific, St. Louis, Mo.). The raw materials were mixed
about 14%. The phosphate solutions were stored at a con
and melted at 1100° C. in a platinum crucible for an hour.
stant temperature of 37° C.
The melt was quenched between two room temperature 60 XRD Investigation of Hydroxyapatite Formation
stainless steel plates and then immediately annealed in an
1 M K2HP0 4 solutions. The XRD pattern of FIG. 4A
electrical furnace at 450° C. for three hours and cooled
shows that the formation of hydroxyapatite upon 45B5-1
overnight. The borate glass was crushed and sieved to
glass spheres reacted in 1 M ly/lPC ^ solution occurs in as
recover particles in the 300-355 micron size range, which
few as 5 days at 37° C. The main XRD peaks of the pattern
were used for implantation.
65 obtained after 5 days of reaction matches closely the 20
Particles in the size range of 75-200 fim were sphelocations and relative intensities of HAp as given by the PDF
roidized at 1000° C. The spheres were sieved to separate
card 9-432.
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0.1 M K2H P04 solutions. The XRD pattern of FIG. 4B
Na2H P04 Solutions
shows that the formation of FIAp occurs in as few as 14 days
A I M phosphate solution was prepared by dissolving an
for the 45B5-1 glass reacted in 0.1 M K2H P04 solution at
appropriate amount of sodium phosphate (Na2H P04) in
37° C. No further change in the XRD pattern is observed
de-ionized water along with 1.5 M HC1. After the sodium
with further reaction of the spheres up to 35 days in the 0.1 5 phosphate dissolved, 1.5 M tris (hydroxymethyl) amiM solution. The XRD pattern shows strong diffraction peaks
nomethane was added to raise the solution pH to 7.0.
for hydroxyapatite for the borate glass spheres reacted in the
The reactions of annealed 45SB1 glass microspheres with
0.1 M K2H P04 solution.
1 M phosphate at 37° C. were observed by optical micros
0.01 M and 0.001 M KdlPO,, solutions. The XRD
copy until the microspheres had fully reacted to leave a
patterns of 45B5-1 glass spheres reacted with 0.01 M and 10 microsphere with no unreacted glass core. To produce larger
0.001 M phosphate solutions show the formation of poorly
amounts of reacted microspheres for characterization,
crystalline HAp. FIGS. 5Aand 5B show the XRD spectra for
annealed 45SB1 microspheres were placed in the 1 M
45B5-1 glass spheres reacted in 0.01 M and 0.001 M
phosphate solution at a glass to solution ratio of 1 mg/ml, at
phosphate solutions at a starting pH of 7 at 37° C., respec
a temperature of 37° C. After 1, 4,11, and 28 days at 37° C.,
tively. The XRD pattern of 45B5-1 glass reacted in the 0.01 15 microspheres were removed from the solution, dehydrated
M solution after 2 weeks shows only a low intensity, diffuse
in a graded series of ethanol (80, 90, and 100%), and
split peak indicated by arrows around 32° to 34° (20). The
analyzed by SEM-EDS and XRD. The external surface of
microspheres reacted for each time was examined by SEM,
XRD pattern seemed unchanged between 2 to 16 weeks for
the glass spheres reacted in the 0.01 M phosphate solution.
and the cross-section of microspheres from the one-day
The XRD pattern of the 45B5-1 glass reacted for up to 9 20 sample was examined by SEM-EDS. The microspheres
weeks in the 0.001 M solution slowly changes towards the
were not heat treated after reacting with the phosphate
low intensity and diffuse split peak mentioned above and
solution.
indicated by arrows in FIG. 5B. After 9 weeks, the XRD
Annealed 45S5 glass microspheres were reacted with 0.25
pattern remains unchanged with further reaction up to 16
M phosphate solution under the conditions described above.
weeks.
25 After 4, 14, and 28 days, microspheres were removed from
the solution, and the external surfaces were examined by
SEM Investigation
SEM. The reacted microspheres were also crushed with a
mortar and pestle and analyzed by XRD. Only the external
The SEM observations of samples of borate spheres
surface of microspheres reacted for each time was examined
reacted in 1 M K2H P04 solution for 1, 4, 11 and 26 days
30 by SEM.
show the presence of a HAp microstructure (FIG. 6). The
1 M and 0.25 M Na2H P04 solutions. Microspheres of
external surface of a reacted sphere is covered with a
45B5-1 glass immersed in the 1 M phosphate solution at 37°
platelike structure at day 1 (FIG. 6A). These small plates,
C. fully reacted in 24 hours, as shown in FIG. 8. The reaction
arranged perpendicular to the surface of the glass, homoge
product was a homogenous gel. FIG. 9 shows XRD patterns
neously cover the entire surface of the reacted spheres at
35 for annealed 45B5-1 microspheres that have been reacted
days 4 and 11 (FIGS. 6B and 6C). At day 26 (FIG. 6D), the
with 1 M phosphate solution for 1, 4, and 11 days at 37° C.,
plates have completely covered the surface of the spheres
and the documented XRD pattern for HAp. These XRD
obstructing the little porosity that remained at day 11. The
patterns indicate the HAp is present along with residual
outer layer covering the glass spheres seems to form a
amorphous material. Although it has been documented, that
impermeable layer that might slow down further bulk dis
40 the crystallization of HAp on a glass surface is dependent on
solution reaction of the glass with the solution, but according
the presence of a silica gel layer, which serves as heteroge
to the IR spectra and XRD diffraction pattern at 26 days of
neous nucleation sites for HAp, these data suggest otherwise
reaction, 45B5-1 glass spheres have already formed a fully
(since 45B5-1 glass contains no silica).
crystalline HAp.
SEM Investigation
The reaction layer formed at days 1 and 4 with platelike, 45
SEM-EDS indicated that the 45S5 microspheres that had
fine structures is more or less ordered and forms a porous
reacted for one day with 1 M phosphate solution at 37° C.
structure. EDS revealed the presence of calcium and phos
had a Ca:P ratio of 1.2, which is calcium deficient with
phorus with a Ca/P ratio of 1.42±0.5 in contrast with the
respect to HAp (Ca:P=1.5 to 1.67). These results are con
HAp stochiometric Ca/P ratio of 1.67. (The platelike par
sistent with the XRD pattern, which showed the presence of
ticles about 50 microns across on the surface of 45B5-1 glass 50 some amorphous material, such as amorphous calcium phos
spheres reacted in 1 M solution do not seem to increase in
phate (ACP), which usually has a Ca:P ratio ranging from
size between 1 and 26 days.) The stability in the size of the
1.2 to 1.5. The cross-sections of the 45B5-1 glass micro
particles between 1 and 26 days indicates that the formation
spheres reacted with 1 M phosphate for 24 hrs at 37° C. is
of calcium phosphate particles on borate glass spheres
shown in FIG. 10. Several of the microspheres shown in
reacted in a 1 M I^HPC^ solution is a uniform and rapid 55 FIG. 10 have a dark spot in the center, which may contain
process that occurs in one day. The same platelike micro
a larger volume fraction PMMA than the rest of the micro
structure was observed on 45B5-1 borate glass spheres
sphere. The dark spot indicates that the reacted microspheres
reacted for one day in a 0.1 M K2H P04 solution.
may have a lower density at the center than at the edges.
Borate glass spheres reacted in the 0.01 M K2H P04
The external surfaces of 45B5-1 microspheres which have
solution for 16 weeks (FIG. 7) also exhibit a platelike, 60 reacted with 1 M phosphate solution for 1, 4,11 and 28 days
porous microstructure. The platelike structure observed on
are shown in FIG. 11. After reacting for one day in 1 M
the sample reacted in 1 M and 0.1 M solution is still present
phosphate solution, the surface of 45B5-1 is covered with
on one of the spheres but a somewhat different morphology
needle-like and plate like crystals of HAp, with a size
is generally observed on the other spheres. Approximately 5
ranging from 5 by 100 nm to 10 by 200 nm. This crystal size
microns underneath the thin layer of plates, a sponge like 65 and shape has also been reported as the structure of HAp
disorganized structure made of smaller plates and a porous
precipitated from a solution and the apatitic component of
network is observed.
natural bone. The initial structure of the crystals was still
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visible after 4 days, but the crystals had grown outward from
Once the particles were placed in the tibia hole, the wound
was closed externally by staple-like metallic clips. All the
the surface to become more plate-like. The crystals also
rats survived the surgery, appeared healthy and showed no
grew to approximately twice the length that they were after
sign of post-surgery infection. The rats were sacrificed at 15,
1 day of reaction with 1 M phosphate solution. After 11 days
in 1 M phosphate solution, both needle-like and plate-like 5 30, 45 and 60 days after implantation. The tibiae recovered
from the rats were fixed in 4% formaldehyde, dehydrated in
crystals appeared to be present. Only plate-like particles are
serial ethanol concentrations and embedded in polymethyl
visible after 28 days of reaction. Both needle-like and
methacrylate (PMMA). At the site of each hole, the tibia was
plate-like morphologies have been reported in the structure
sectioned with a diamond saw, polished with 1 fim diamond
of the apatitic component of bone. However, the crystals
formed by reactions longer than one day were larger than 10 paste and coated with a gold palladium film for examination
in a Hitachi S-570 (Hitachi, Japan) or Jeol T330 A (Jeol,
those present in natural bone, which are typically 40 by 20
Japan) SEM.
nm or smaller.
When 45S5 glass microspheres were reacted with the 0.25
Backscattered electron (BSE) imaging was used to deter
M phosphate solution at 37° C., for 14 and 28 days, XRD
mine the degree of bone growth for each implantation
showed that HAp was present. The reaction layer on the 15 periods. In back-scattered mode, the light colored regions
particles was only -10 fim thick. A glassy core appeared in
correspond to elements with a higher atomic number while
each microsphere, which accounts for the high background
the darker regions contain elements of lower atomic num
bers. New bone generally had a medium to light gray color
in the XRD pattern. The surface of 45S5 glass microspheres
reacted with 0.25 M phosphate solution consisted of needle
and un-mineralized calcium phosphate was a whiter, light
like HAp crystals. Microspheres reacted for 28 days, 20 gray color. Hie unreacted glassy core of the particles was a
retained the needle-like structure seen after 14 days of
dark gray color.
reaction and the XRD pattern did not change significantly.
Reaction of the Borate Glass Particles In Vivo
This retention of structure differed from the reactions of
The 45B5-1 glass particles had a glassy, dark core in the
45B5-1 glass with 1 M phosphate solution, where the
center of the particles surrounded by a continuous layer. Uiis
morphology of the HAp crystals changed from needle-like 25 white layer was identified by EDS to be calcium phosphate
to plate-like and the crystals grew.
rich with a calcium to phosphorus ratio of 1.45±0.1
(stochiometric HAp has a Ca/P ratio of 1.67). XRD analysis
Example—3
revealed that the crystalline calcium phosphate rich layer,
initially too thin to give any diffraction pattern, became
In Vivo Use
30 detectable in as little as 11 days. Black lines drawn on some
Prior to surgery, the glass powder was made as described
of the figures denote the edges of the initial hole in the tibia.
in Example 1, and then stored in glass vials tightly covered
Reaction after 15 days. New bone formation (medium
with aluminum foil and heat sterilized at 450° C. in an
gray in color) was observed as early as 15 days around some
electrical furnace for 3 hours. To promote the formation of
particles (FIG. 12). New bone indicated by the arrows was
a calcium phosphate rich layer on the surface of the bioac 35 also visible at the edge of the hole, even though the original
tive glass particles and to increase the formation rate of the
hole was not completely filled at 15 days. The average
new bone, the borate glass particles were pre-reacted for 24
thickness of the reacted surface layer on the 45B5-1 glass
hours in 1 M Na2H P04 solution. The reacted surface layer
particles slightly increased from 60 ,Mn±20 to 80 fim±20.
that formed in 24 hours on the glass particles consisted of an
The particles of 45S5 glass and 45B5-1 glass seemed to stay
amorphous calcium phosphate rich layer, with an average 40 in place at the edge of the cavity. The rapid formation of
thickness, as determined by SEM, of 60 fim±20 and was
bone indicates that the pre-reacted surface is a suitable
identified as composed of needle-like or small (300-600 nm)
environment for bone bonding or growth.
plates standing nearly perpendicular to the surface of the
Reaction after 30 days. After 30 days in vivo, both the
glass. This platelike structure was very similar to the struc
45B5-1 (FIG. 13) and the 45S5 glass particles were largely
ture observed on particles reacted under the same conditions 45 in contact with new bone. A layer of porous new bone closed
in 1 M K^HPC^ solutions.
the hole in all cases. The reacted layer did not seem to
45S5 silicate glass particles were obtained from Mo-Sci
increase in thickness around the 45S5 glass (approx. 30 to 50
Corp. (Rolla, Mo.) and used in their as received state. After
microns thick after 30 days in the rat). This surface layer was
receipt, they were stored in glass vials tightly covered with
easily visible around the dark core of the 45S5 particles.
aluminum foil and heat sterilized at 500° C. in an electrical 50
The unreacted core of the silica-free borate glass particles
furnace for 3 hours. Particles in the size range of 300-355
surrounded with new bone did not shrink. The thickness of
micron were used for implantation. The particles of 45S5
the surface layer surrounding the 45B5-1 glass particles was
glass and particles of 45B5-1 glass were implanted in the
still approximately 80 ,Mn±20 after 30 days, but the lighter
upper part of the tibia of 12 mature male rats. The rats were
surface layer on the borate particles had cracked and in some
anesthetized with a xylazine-ketamine mixture injected 55 cases separated from the medium gray core.
intraperitoneally. A 0.5 mm diameter dental drill, was used
In general, the new bone that had formed around the
under phosphate buffered solution (PBS) irrigation, to make
pre-reacted borate particles after 30 days appeared denser
two holes in each tibia that penetrated into the bone marrow
(with smaller pores) and thicker than the bone associated
region. The resulting holes in the tibia of the rats were
with the 45S5 glass particles. However, it should be recalled
between 0.6 to 1.2 mm in diameter.
60 that even though the borate glass particles were pre-reacted
The glass particles were loosely packed in a glass capil
before implantation, the calcium phosphate layer grown in
lary tube 0.5 mm in diameter. Pressure applied on a plunger
vitro was only about 60 microns in thickness.
introduced in the capillary tube released the glass particles
Reaction after 60 days. After 60 days in the rat, the holes
in the hole. Contact of the capillary tube with body fluids had
were completely closed and it was often difficult to distin
to be avoided since the fluids would instantly wet the glass 65 guish between the old and new bone. It was difficult to
particles and prevent them from sliding out of the capillary
distinguish the residual core of the 45B5-1 glass particles,
tube hole.
which were embedded in the new bone. Hie entire borate
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particles (light gray) were surrounded by dense new bone.
14. The process of claim 13 wherein the material is
However, a dark core was still visible in many of the 45B5-1
ceramic.
particles trapped in the marrow cavity.
15. The process of claim 13 wherein the material is glass.
Unlike the borate particles, the 45S5 glass particles sur
16. The process of claim 13 wherein the material is
rounded by new bone still contained a visible dark core most 5 glass-ceramic.
likely because they were not fully reacted after 60 days in
17. The process of claim 13 wherein x is from about 22%
vivo.
to about 30%, y is from about 22% to about 30%, z is from
The foregoing specification is meant to illustrate the
about 5% to about 6%, q is from about 35% to about 50%.
invention, and not limit it in any way. Those skilled in the
18. The process of claim 13 wherein x is about 22.9%, y
art will recognize that modifications of little or great degree 10 is about 22.9%, z is about 5.6% and q is about 48.6%.
can be made which are within the spirit and scope of the
19. The process of claim 13 wherein the aqueous solution
many embodiments of this invention as defined in the
is Na2HP04.
appended claims.
20. The process of claim 13 wherein the aqueous solution
What is claimed is:
is iqHPCy.
1. A bioactive material having the formula
15
21. The process of claim 13 wherein the phosphate
solution has a concentration of about 0.001 M to about 1 M.
xNa20.yCa0.zP20 5.qB20 3
22. The process of claim 21 wherein the phosphate
solution has a concentration of about 0.01 M to about 0.25
wherein x is from about 20% to about 35%;
20 M.
y is from about 20% to about 35%;
23. The process of claim 13 wherein the initial pH is in the
z is from about 0% to about 10 %; and
range of about 6 to about 10 .
q is from about 30% to about 50%.
24. The process of claim 23 wherein the initial pH is about
2. The bioactive material of claim 1 wherein the material
7.
is ceramic.
25
25. The process of claim 13 wherein the temperature is in
3. The bioactive material of claim 1 wherein the material
the range of about 30° C. to about 60° C.
is glass.
26. The process of claim 25 wherein the temperature is
4. The bioactive material of claim 1 wherein the material
about 35° C. to about 57° C.
is glass-ceramic.
27. The process of claim 13 wherein the temperature is
5. The bioactive material of claim 1 wherein the material
30 about 37° C.
is at least partially crystalline.
28. The process of claim 13 wherein said time is from
6. The bioactive material of claim 1 having a calcium
about 4 hours to about 14 days.
phosphate surface layer thereupon.
7. The bioactive material of claim 6 wherein the calcium
29. The process of claim 28 wherein the time is from
phosphate layer is hydroxyapatite.
about 5 days to about 14 days.
35
8. The bioactive material of claim 1 which forms a
30. The process of claim 13 wherein the time is about 24
calcium phosphate layer when in contact with a physiologi
hours.
cal solution.
31. The process of claim 13 wherein the material is
9. The bioactive material of claim 1 wherein x is from
comprised of particles.
about 22% to about 30%, y is from about 22% to about 30%,
32. The process of claim 31 wherein the glass has a
40
z is from about 5% to about 6%, q is from about 35% to
particle size range from about 1 fim to about 400 fim.
about 50%.
33. The process of claim 32 wherein the glass has a
10. The bioactive material of claim 1 wherein x is about
particle size range from about 40 fim to about 300 fim.
22.9%, y is about 22.9%, z is about 5.6% and q is about
34. The process of claim 33 wherein the glass has a
48.6%.
45 particle size range from about 60 fim to about 250 fim.
11. The bioactive material of claim 1 wherein the glass is
35. The process of claim 13 wherein the glass has a
comprised of particles.
particle size range from about 75 fim up to about 1 mm.
12. A particulate borate ceramic, the particles of the
ceramic being at least a partial calcium phosphate layer
36. The process of claim 13 wherein the material is
thereupon.
generally spherical.
50
13. A process for providing a bioactive material compris
37. The process of claim 13 wherein the material is in
ing r e a c t i n g a m a t e r i a l h a v i n g the f o r mu l a
morsel form.
xNa20.yCa0.zP20 5.qB20 3:
38. The process of claim 13 wherein the material is in bulk
wherein x is from about 20% to about 35%;
form.
y is from about 20% to about 35%;
55
39. The process of claim 13 wherein the material is
fibrous.
z is from about 0% to about 10 %; and
40. The process of claim 13 wherein the material is
q is from about 30% to about 50%;
foliaceous.
with an aqueous solution comprising phosphate ions for a
time sufficient to form calcium phosphate upon said mate
rial.

